Cart
sales@molnova.com
AN-019
CAS No. 879507-25-2
AN-019( —— )
Catalog No. M34157 CAS No. 879507-25-2
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAN-019
-
NoteResearch use only, not for human use.
-
Brief DescriptionAN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
-
DescriptionAN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number879507-25-2
-
Formula Weight517.43
-
Molecular FormulaC25H17F6N5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC=C(C(=C1)NC=2N=CC=C(N2)C3=CN=CC=C3)C)C=4C=C(C=C(C4)C(F)(F)F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DCC-2036
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.
-
BCR-ABL-IN-7
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
-
Dasatinib
A potent, orally bioavailable, dual Src/Abl kinase inhibitor.
